| Trial ID: | L4593 |
| Source ID: | NCT01552018
|
| Associated Drug: |
Saxagliptin
|
| Title: |
Saxagliptin and Atherosclerosis
|
| Acronym: |
SAXATH
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Coronary Artery Disease|Diabetes Mellitus Type 2
|
| Interventions: |
DRUG: Saxagliptin|DRUG: Placebo
|
| Outcome Measures: |
Primary: Inflammatory biomarkers, A selection of biomarkers associated with atherosclerosis, circulating levels and gene expression levels in adipose tissue and leukocytes., Changes in biomarkers from baseline to 3 months | Secondary: Gene expression of DPP-4 in adipose tissue and leukocytes, Change in expression level of DPP-4 from baseline to 3 months
|
| Sponsor/Collaborators: |
Sponsor: Oslo University Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
12
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2012-03
|
| Completion Date: |
2014-02
|
| Results First Posted: |
|
| Last Update Posted: |
2014-06-18
|
| Locations: |
Center for Clinical Heart Research, Dept. of Cardiology, Oslo University Hospital Ullevaal, Oslo, N-0424, Norway
|
| URL: |
https://clinicaltrials.gov/show/NCT01552018
|
